Livedoid vasculopathy: a compelling diagnosis by Freitas, Thiago Quadrante et al.
Autopsy and Case Reports. ISSN 2236-1960. Copyright © 2018. This is an Open Access article distributed 
under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted 
non-commercial use, distribution, and reproduction in any medium provided the article is properly cited.
a Universidade de São Paulo (USP), Faculty of Medicine, Internal Medicine Department. São Paulo, SP, Brazil.
b Universidade de São Paulo (USP), Hospital das Clínicas, Dermatopathology Laboratory, Dermatology Division. São Paulo, SP, Brazil.
c Universidade de São Paulo (USP), Faculty of Medicine, Department of Dermatology. São Paulo, SP, Brazil.
d Faculty of Medicine of ABC, Department of Dermatology. Santo André, SP, Brazil.
Livedoid vasculopathy: a compelling diagnosis
Thiago Quadrante Freitasa, Ilana Halpernb, Paulo Ricardo Criadoc,d
How to cite: Freitas TQ, Halpern I, Criado PR. Livedoid vasculopathy: a compelling diagnosis. Autops Case Report 
[Internet]. 2018;8(3):e2018034. http://dx.doi.org/10.4322/acr.2018.034
Letter to the Editor
DEAR EDITOR
The goal of our letter is to catch the medical 
community’s eye regarding an unusual diagnosis, 
which may be overlooked or diagnosed late because 
of lack of familiarity or even knowledge on the part of 
the vast majority of clinicians and general practitioners.
Livedoid vasculopathy (LV) is a rare disease, 
with an estimated incidence of 1:100,000 per year 
with a male to female ratio of 1:3, particularly from 
15 to 50 years old.1-3 The most relevant epidemiologic 
characteristic is the 5-year delay of accurate diagnosis 
and treatment.2
In 1955, Feldaker et al.1 first described the 
entity and named it livedo reticularis with summer 
ulcerations. Since then, segmental hyalinizing vasculitis 
and Milian’s atrophie blanche are among many other 
recognized synonymy. However, it is accepted that 
“livedoid vasculopathy” is an appropriate name due 
to its descriptive labeling, since its focal vascular 
occlusions are not caused by vasculitis.2
The clinical manifestations are recurrent and 
begin with a focal non-inflammatory thrombosis of 
the venulae of the superior superficial and medium 
dermis, especially on the lower extremities, bilaterally; 
however, involvement of the upper extremities has 
also been reported.3 Such thrombosis leads to blood 
and pressure build-up in the superficial veins of the 
dermis, which manifests as livedo racemosa or, less 
frequently, livedo reticularis.4 As a consequence of the 
blood flow obstruction, the oxygen partial pressure in 
the skin diminishes, which starts a cutaneous response 
that is manifested as pruritus with painful papules 
and erythematous-violaceous, purpuric plaques.3 
They rapidly evolve into hemorrhagic vesicles or bullae 
that, when ruptured, become painful small ulcers 
of roughly 5 mm in diameter, which tend to merge 
into reticulate, confluent, geometric, and painful 
ulcerations3 (Figure 1A and 1B). During the disease 
activity, lesions in different stages coexist, and early 
treatment may halt the development of new lesions.2 
During a period of 3 to 4 months, the ulcerations 
change to a porcelain-white atrophic scarring tissue 
with punctate telangiectasia: the so-called Milian’s 
atrophie blanche or capillaritis alba (Figure 1B).3,4
The main acute complications are pain and 
secondary infection due to the exposure of the 
tissue. LV also results in several chronic complications, 
such as atrophic scars, residual hyperpigmentation, 
mononeuritis multiplex due to vasa nervorum 
thrombosis, and cutaneous hemosiderosis in the lower 
extremities because of erythrocytes pouring out from 
the high-pressure regimen veins, due to hemosiderin 
deposits in the skin.3
Differential diagnoses that must be excluded 
are (i) gangrenous pyoderma, especially when 
a secondary infection is present; (i i) factitious 
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dermatitis, which presents only with ulcerations 
(without papules or vesicles); and (iii) cutaneous 
polyarteritis nodosa, which typically starts with painful 
subcutaneous nodules. Other differential diagnoses 
include leukocytoclastic vasculitis, pseudo-Kaposi 
sarcoma or acroangiodermatitis of Mali, Degos disease, 
and chronic venous stasis.2,3
Even though the clinical manifestation may seem 
fairly characteristic, the diagnosis is histopathological. 
Figure 1. Gross view of the livedoid vasculopathy 
lesions. A – Note the presence of purpuric plaques that 
merged forming ulcerating lesions, and the coexistence 
of varying-degree lesions; B – The purpuric lesions are 
surrounded by an erythematous ring; the arrow points 
to the porcelain-white atrophic scarring tissue.
Figure 2. Photomicrography of the skin biopsy showing an intravascular thrombus (inset). Note the absence of 
perivascular inflammation and leukocytoclasia.
It is believed that the benefits of a skin biopsy outweigh 
the theoretic possibility of an ulcerous formation in its 
place, since it prompts earlier treatment.3 A deep punch 
or excisional biopsy should be performed in an active 
lesion avoiding the necrotic areas. Initially, histology 
shows fibrin thrombi inside the lumina of small vessels 
without evidence of inflammation (Figure 2).
Later, more significant fibrin deposition in the 
lumen and in the vascular walls with secondary 
areas of infarction or ulceration are noted (Figure 3). 
At the periphery of the vessels, fibrin deposits can be 
present creating the characteristic hyalinized fibrin 
rings, with mild or absent lymphocytic infiltrate or 
signs of vasculitis.2,3 Red blood cell extravasation and 
neutrophilic infiltrate secondary to the ulceration can 
be seen.3
Later, while maintaining the hyalinized fibrin 
thrombus, the walls of affected vessels thicken and 
endothelial cells proliferate in response.3 The absence 
of exuberant neutrophil infiltration, perivascular nuclear 
fragmentation (leukocytoclasia), and fibrinoid necrosis 
of blood vessels define this pathology as a vasculopathy 
rather than vasculitis. Direct immunofluorescence 
exhibits non-specific fibrin, immunoglobulin, and 
complement deposition, but it does not provide any 
additional diagnostic information.3
LV should not be understood as a unique pathology, 
but rather as a cutaneous manifestation of many other 
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prothrombotic diseases that disturb any—or more than 
one—vertex of Virchow’s triad. The disturbances in 
blood stasis are related to hyperviscosity syndromes, 
such as chronic myeloid leukemia, heavy chain 
diseases, and cryoglobulinemia.3 Diseases associated 
with LV that cause endothelial injury are systemic 
erythematous lupus (anti-cardiolipin antibodies and 
lupus anticoagulant are found in a fraction of patients 
with LV),2,3 as well rheumatoid arthritis, scleroderma, 
and hyperhomocysteinemia.3 The Leiden factor V 
mutation, proteins C, S, Z, anti-thrombin deficiencies, 
elevated levels of plasminogen activator inhibitor 
type 1 (PAI-1), and lipoprotein(a) are entities that lead 
to hypercoagulability and may be associated with LV.3
Therefore, diagnostic investigation should not 
end with a conclusive biopsy. Serum complement 
and anti-neutrophil cytoplasmic antibodies are 
important because they are usually altered in most 
true vasculitis.3 Screening for autoimmune diseases 
is also recommended with antinuclear antibodies, 
rheumatoid factor, and anti-cyclic citrullinated peptide 
antibodies. Paraproteinemia should be excluded 
after normal serum protein electrophoresis, serum 
cryoglobulin levels, and negative proteinuria; testing 
for HIV plus hepatitis B and C is also important in 
such a context.2,3 Dosing coagulation factors and 
their mutations are relevant for excluding hereditary 
and acquired thrombophilia.2 However, even after a 
thorough laboratorial investigation, up to 20% of the 
cases of LV are stated as idiopathic.3
A systematic review on LV treatment was published 
in November 2017,5 but it remains non-standardized 
because the evidence relies mostly on case reports 
and case series.6 Anticoagulants are the most 
common monotherapy, particularly rivaroxaban, but 
unfractionated and low-molecular-weight heparin 
also can be used—all of which have bleeding as 
a common side effect. The second most common 
monotherapy is danazol because of its interference 
with the hepatic synthesis of coagulation factors. 
Glucocorticoids also are used, but have lower success 
rates,5 which is probably due to the non-immune or 
pauci-immune characteristic of this entity, except for 
the cases related to other autoimmune or connective 
tissue diseases.5 Anti-platelet agents are the drugs most 
often used for LV in Brazil, including acetylsalicylic acid, 
pentoxifylline, cilostazol,3 and dipyridamole, which 
are administered either as monotherapy or combined. 
Recently, PAI-1 mutations related to LV were described, 
which prompted the use of thrombolytic drugs, such 
as the recombinant tissue plasminogen activator 
(rtPA),5 which bypasses the inhibition of tPA by the 
mutated PAI-1,3 with some promising outcomes. Other 
therapeutic agents, such as psolaren UV-A, hyperbaric 
oxygen, intravenous immunoglobulin, sulfasalazine, 
and nicotinic acid,5 have been studied but show lower 
efficacy.
In clinical practice, vasculitis—or skin lesions 
interpreted as vasculitis—is a constant challenge to 
the clinician; it often remains underdiagnosed or is 
diagnosed late. With this letter, we aimed to present 
this entity for those clinicians who are not aware of it, 
and to refresh the memory of those who are.
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Figure 3. Photomicrography of the skin biopsy. A – Epidermal ischemic necrosis secondary to the vascular occlusion; 
B – Vascular thrombi with fibrin deposits in the lumen and in the vascular wall in the mid dermis. Note the lack of 
leukocytoclasia or lymphocytic infiltrate.
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